



## **Transmucosis strengthens leadership team with the appointment of Christine Czarniecki for development/regulatory, and Andre Hoekema as CBO**

- *Dr. Czarniecki and Dr. Hoekema each have over 40 years of experience in pharmaceutical drug development and life science leadership*
- *Accelerates our ambition to develop nasal vaccine platform and pursue pharma relationships*

**College Park MD, USA, 21 June 2023** – Transmucosis LLC (“Transmucosis” or the “Company”), a private biotechnology company pioneering a novel intranasal vaccine platform, today announces the strengthening of its leadership team with the appointments of Christine Czarniecki as Head of Development and Regulatory Affairs, and Andre Hoekema as Chief Business Officer.

Dr. Christine W. Czarniecki’s career spans from basic research through the critical path of product development to license application and post-marketing activities. After her Ph.D. from Georgetown University she served as a post-doc at the NIH. At Genentech Inc., ICOS Corp. and Axyx Pharmaceuticals, Inc. she was responsible for Regulatory affairs and oversaw contacts between the companies and the FDA. More recently, from 2002 to April 2023, she led Regulatory Affairs and Quality Assurance at NIAD/NIH to provide regulatory guidance for all clinical trials under IND Sponsorship. Her responsibilities also included Regulatory CRO management, vendor audits, managing negotiation of Clinical Trial Agreements with Pharma drug manufacturers.

Dr. Andre Hoekema (PhD from Leiden University) started his career as a post-doc at Genentech, Inc. He is a highly experienced and successful biotech executive with 40 years’ experience in the industry. He served as Chief Business Officer and member of the Executive Committee at Galapagos Pharma for 18 years, with responsibility spanning M&A, business development and IP. During his time at Galapagos, he led multiple pharma partnerships, acquisitions and divestments, including two landmark deals with Gilead. He was also part of the team that completed successful IPOs on Euronext (2005) and Nasdaq (2015). Andre serves as a member of the supervisory advisory boards of Artax Biopharma (Cambridge MA, USA), and Fibrocor Therapeutics (Toronto, CA).

Herbert Heyneker, CEO of Transmucosis, said: “Following the preclinical proof of concept of our vaccines against influenza, COVID-19 and RSV, we are looking forward to rapidly progress our development candidates to clinical development. Christine’s and Andre’s wealth of experience in the sector and their significant track records will be invaluable as we grow the business.”

-ENDS-

For more information, please contact:

Transmucosis LLC

Herbert Heyneker, CEO

[hheyneker@transmucosis.com](mailto:hheyneker@transmucosis.com)

### **About Transmucosis**

Transmucosis is a developer of protein-based intranasal vaccines against respiratory diseases. It leverages the unique properties of the FcRn receptor to facilitate the passage of nasal vaccines across the mucosal surface. Transmucosis developed multiple influenza vaccines. Furthermore, the



company obtained preclinical proof of concept with intranasal vaccines against all tested strains of coronavirus, and against RSV. Transmucosis LLC was founded by Dr. Herbert Heyneker (CEO) and Prof. Dr. Xiaoping Zhu (CSO). Transmucosis signed an exclusive license agreement with the University of Maryland covering all research on the intranasal vaccine platform by the lab of Prof. Zhu's. The lab has been funded for more than a decade by NIH and other grants. The company is located at 8075 Greenmead Drive, College Park, Maryland 20742-3711, USA.